MX2025004633A - 1,3,5-triazinas 2,4,6-trisustituidas como moduladores del receptor 1 de quimiocina con motivo cx3c (cx3cr1) - Google Patents
1,3,5-triazinas 2,4,6-trisustituidas como moduladores del receptor 1 de quimiocina con motivo cx3c (cx3cr1)Info
- Publication number
- MX2025004633A MX2025004633A MX2025004633A MX2025004633A MX2025004633A MX 2025004633 A MX2025004633 A MX 2025004633A MX 2025004633 A MX2025004633 A MX 2025004633A MX 2025004633 A MX2025004633 A MX 2025004633A MX 2025004633 A MX2025004633 A MX 2025004633A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- trisubstituted
- modulators
- triazines
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen ciertos compuestos 1,3,5-triazina 2,4,6 trisustituidos de la Fórmula (I), (I) y sales farmacéuticamente aceptables de estos, junto con composiciones que los contienen y su uso en terapia. Los compuestos son moduladores de CX3CR1 y de esta manera son particularmente útiles en el tratamiento o profilaxis de trastornos cardiovasculares tales como miocardiopatía dilatada no isquémica e insuficiencia cardíaca.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263417472P | 2022-10-19 | 2022-10-19 | |
| PCT/EP2023/079035 WO2024083933A1 (en) | 2022-10-19 | 2023-10-18 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3cr1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025004633A true MX2025004633A (es) | 2025-06-02 |
Family
ID=88511235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025004633A MX2025004633A (es) | 2022-10-19 | 2025-04-21 | 1,3,5-triazinas 2,4,6-trisustituidas como moduladores del receptor 1 de quimiocina con motivo cx3c (cx3cr1) |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20240199558A1 (es) |
| EP (1) | EP4605388A1 (es) |
| JP (1) | JP2025537492A (es) |
| KR (1) | KR20250086780A (es) |
| CN (1) | CN120077035A (es) |
| AR (1) | AR130808A1 (es) |
| AU (1) | AU2023362450A1 (es) |
| CL (1) | CL2025001155A1 (es) |
| CO (1) | CO2025006339A2 (es) |
| CR (1) | CR20250196A (es) |
| DO (1) | DOP2025000096A (es) |
| IL (1) | IL320305A (es) |
| MX (1) | MX2025004633A (es) |
| PE (1) | PE20251587A1 (es) |
| TW (1) | TW202430188A (es) |
| UY (1) | UY40495A (es) |
| WO (1) | WO2024083933A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20251587A1 (es) * | 2022-10-19 | 2025-06-16 | Astrazeneca Ab | 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1 |
| WO2025219939A1 (en) * | 2024-04-17 | 2025-10-23 | Astrazeneca Ab | Salts and polymorphs of cx3cr1 modulators |
| WO2025219950A1 (en) * | 2024-04-18 | 2025-10-23 | Astrazeneca Ab | Small molecule cx3cr1 modulators |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19960683A1 (de) * | 1999-12-15 | 2001-08-23 | Aventis Cropscience Gmbh | Substituierte 2,4-Diamino-1,3,5-triazine, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| SE0101082D0 (sv) | 2001-03-27 | 2001-03-27 | Astrazeneca Ab | Novel use |
| WO2005033115A1 (en) | 2003-10-07 | 2005-04-14 | Astrazeneca Ab | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 |
| GB0401269D0 (en) | 2004-01-21 | 2004-02-25 | Astrazeneca Ab | Compounds |
| AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| CN101522693B (zh) | 2006-09-29 | 2012-01-04 | 阿斯利康(瑞典)有限公司 | 5,7-二取代的[1,3]噻唑并[4,5-d]嘧啶-2(3h)-胺衍生物和它们在治疗中的用途 |
| TW200820973A (en) | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
| AR071036A1 (es) | 2008-03-26 | 2010-05-19 | Astrazeneca Ab | Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1. |
| TWI543975B (zh) | 2011-09-13 | 2016-08-01 | Eisai R&D Man Co Ltd | Pyrrolidin-3-yl acetic acid derivatives |
| EA201591291A1 (ru) | 2013-01-08 | 2015-12-30 | Савира Фармасьютикалз Гмбх | Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания |
| PE20251587A1 (es) * | 2022-10-19 | 2025-06-16 | Astrazeneca Ab | 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1 |
-
2023
- 2023-10-18 PE PE2025000841A patent/PE20251587A1/es unknown
- 2023-10-18 WO PCT/EP2023/079035 patent/WO2024083933A1/en not_active Ceased
- 2023-10-18 EP EP23793744.6A patent/EP4605388A1/en active Pending
- 2023-10-18 AU AU2023362450A patent/AU2023362450A1/en active Pending
- 2023-10-18 US US18/489,184 patent/US20240199558A1/en active Pending
- 2023-10-18 JP JP2025522722A patent/JP2025537492A/ja active Pending
- 2023-10-18 CN CN202380073898.2A patent/CN120077035A/zh active Pending
- 2023-10-18 CR CR20250196A patent/CR20250196A/es unknown
- 2023-10-18 IL IL320305A patent/IL320305A/en unknown
- 2023-10-18 KR KR1020257016242A patent/KR20250086780A/ko active Pending
- 2023-10-19 AR ARP230102794A patent/AR130808A1/es unknown
- 2023-10-19 UY UY0001040495A patent/UY40495A/es unknown
- 2023-10-19 TW TW112139976A patent/TW202430188A/zh unknown
-
2024
- 2024-07-24 US US18/783,231 patent/US12404253B2/en active Active
-
2025
- 2025-04-16 DO DO2025000096A patent/DOP2025000096A/es unknown
- 2025-04-16 CL CL2025001155A patent/CL2025001155A1/es unknown
- 2025-04-21 MX MX2025004633A patent/MX2025004633A/es unknown
- 2025-05-16 CO CONC2025/0006339A patent/CO2025006339A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240199558A1 (en) | 2024-06-20 |
| UY40495A (es) | 2024-05-15 |
| AU2023362450A1 (en) | 2025-05-29 |
| IL320305A (en) | 2025-06-01 |
| US20240383866A1 (en) | 2024-11-21 |
| DOP2025000096A (es) | 2025-07-15 |
| TW202430188A (zh) | 2024-08-01 |
| US12404253B2 (en) | 2025-09-02 |
| CN120077035A (zh) | 2025-05-30 |
| CL2025001155A1 (es) | 2025-08-29 |
| CR20250196A (es) | 2025-11-21 |
| EP4605388A1 (en) | 2025-08-27 |
| AR130808A1 (es) | 2025-01-22 |
| WO2024083933A1 (en) | 2024-04-25 |
| PE20251587A1 (es) | 2025-06-16 |
| KR20250086780A (ko) | 2025-06-13 |
| JP2025537492A (ja) | 2025-11-18 |
| CO2025006339A2 (es) | 2025-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| CO2025006339A2 (es) | 1,3,5-triazinas 2,4,6-trisustituidas como moduladores de cx3cr1 | |
| MX2024013838A (es) | Compuestos y usos de estos | |
| MX2023004149A (es) | Degradadores de moléculas pequeñas de piperidinilo de helios y procedimientos de uso. | |
| CR20230566A (es) | Derivados de triazina y su uso en el tratamiento del cáncer | |
| PH12022553530A1 (en) | 1'-cyano nucleoside analogs and uses thereof | |
| GEAP202416135A (en) | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors | |
| MX2022005232A (es) | Degradadores de moleculas peque?as de helios y procedimientos de uso. | |
| EA202191801A1 (ru) | Гетероциклические ингибиторы mat2a и способы применения для лечения рака | |
| DK0611368T3 (da) | Substituerede aminopyrimidiner som angiotensin II-antagonister | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| PH12022551767A1 (en) | Sulfonimidamide compounds as nlrp3 modulators | |
| MX2024004131A (es) | Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1. | |
| ES2060951T5 (es) | Azaindenos. | |
| MX2024011120A (es) | Pirimidinas para degradar la tirosina cinasa de bruton. | |
| MX2023009954A (es) | Compuestos de aminopirimidina y métodos de uso de estos. | |
| MX2025002166A (es) | Compuestos y metodos para modular her2 | |
| MX2024007395A (es) | Tetrahidropiridazinas, composiciones que las comprenden y usos de estas. | |
| MX2024013842A (es) | Benzoyparazina pirazinas y sus usos | |
| GEAP202516820A (en) | Prmt5-mta inhibitor | |
| MX2025013649A (es) | Compuesto de oxazolona sustituida para reducir los niveles de proteinas con dedos de zinc ikaros (ikzf) 1-4 | |
| MX2024000634A (es) | Compuestos de sulfonimidamida y usos de los mismos. | |
| WO2019202346A3 (en) | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms |